Table 1.

In vivo evaluation of the ability of Bortezomib to prevent diaphragmatic tumor formation in a model of malignant mesothelioma

Diaphragm involvementBortezomib dose
Control (0 mg/kg)0.5 mg/kg1.0 mg/kg
Massive5/90/130/11
Moderate1/90/130/11
Mild2/92/130/11
None1/911/1311/11
  • NOTE: About 1.3 to 1.6 × 107 REN cells were injected i.p. in nude xid mice; 3 d after tumor inoculation treatment with Bortezomib at dosages of 0.5 or 1.0 mg/kg/day was started. Drug was given i.p. twice weekly for 4 wk. Control animals received single i.p. bolus injection of vehicle alone. Two different trials using the same experimental conditions were done. The table summarizes the antitumor activity of Bortezomib as assessed by the extent of diaphragm involvement (classified as none, mild, moderate, or massive; see Materials and Methods).